CD133 Act as an Essential Marker in Ovarian Carcinogenesis

Asian Pac J Cancer Prev. 2021 Nov 1;22(11):3525-3531. doi: 10.31557/APJCP.2021.22.11.3525.

Abstract

Objective: To analyze the role of cancer stem cells (CSC) in ovarian carcinogenesis through the identification of CD133 expression in the normal ovary (NO), serous cystadenoma (SC), borderline serous tumour (BST), low-grade serous carcinoma (LGSC), and high-grade serous carcinoma (HGSC).

Materials and methods: A total of 48 tissue samples contain 5 NO, 10 SC, 5 BST, 8 LGSC, and 20 HGSC were stained with anti-CD133 antibody by immunohistochemical protocol. The difference in the H-score of CD133 expression between groups and their relationship to age, histomorphology, and localization was analyzed.

Results: CD133 expression varied among tumor groups, with clinicopathologic parameters showing diverse associations (age p = 0.773; histomorphology p = 0.001; and localization p = 0.026). The comparison of CD133 H-scores differed significantly between each group (p = 0.0031), in which precursor and malignant lesions possessed more robust CD133 expression.

Conclusion: The presence of CD133 cellular expression and localization in different types of serous ovarian tumours suggests that these markers are involved in ovarian tumorigenesis.

Keywords: CD133; Cancer stem cells; Ovarian Cancer; carcinogenesis.

MeSH terms

  • AC133 Antigen / metabolism*
  • Adult
  • Biomarkers, Tumor
  • Carcinogenesis / genetics
  • Cystadenocarcinoma, Serous / genetics*
  • Cystadenoma, Serous / genetics*
  • Female
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Neoplastic Stem Cells / metabolism
  • Ovarian Neoplasms / genetics*
  • Ovary / metabolism

Substances

  • AC133 Antigen
  • Biomarkers, Tumor
  • PROM1 protein, human